Published in Health and Medicine Week, September 16th, 2002
New analysis from Frost & Sullivan, "U.S. Chronic Obstructive Pulmonary Disease Therapies Markets", reveals that this industry generated revenues totaling $1.89 billion in 2001. Total market revenues could reach $2.97 billion in 2008.
The growing acceptance of long-acting beta2 agonist therapies is the major driver behind growth in market revenues. According to Frost & Sullivan Industry Analyst T. O'Connell, "The efficacy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.